Contract notice: Pharmaceutical products

• Country: Germany
• Summary: Contract notice: Pharmaceutical products
• DET Ref No: 35620368
• Deadline: 05 Aug 2021
• Financier: Self Financed
• Purchaser Ownership: Government
• Tender Value: Refer Document
• Notice Type: Tender
• Document Ref. No.: 392364-2019
• Purchaser's Detail:
  Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details.

  Login to see details
• Description:
• Object of the contract
  Pharmaceutical products
  
  Description: Contract notice: Pharmaceutical products
  
  Authority Type: Body governed by public law
  Contact Nature: Supplies
  Procedure: Open procedure
  Document: Contract notice
  Regulation: European Union
  Award criteria: Lowest price
  CPV code: 33600000,33600000
  CPV Description: Pharmaceutical products.
  Conclusion of a non-exclusive discount agreement according to - 130a Abs. 8 SGB V on the active ingredient glycerol trinitrate, ATC C01DA02, for the period 1.10.2019 30.09.2021
  Reference Number: 1002713 - Glycerol trinitrate, ATC C01DA02
  - 130a Abs SGB V allows the health insurance companies and pharmaceutical companies, framework discount contracts over the burden of the statutory health insuranceto close the medicinal product to be dispensed. In view of the pertinent legal regulations for the awarding of public contracts, a regular process of active substance-related, public procurement procedures takes place according to the regulations of the 4th part of the GWB by the DAK-G. For the medicinal product to be named by the tenderer in Annex 2 to the contract for the active substance Glyceroltrinitrat, ATC C01DA02, intends to conclude drug discount contracts with all interested pharmaceutical companies pending the entry into force of new drug rebates. A discount contract within the scope of the approval model for the o. G. Active ingredient enters into force for the first time on 1.10.2019 and ends on 30.9.2021. It automatically ends with entry into force, regardless of thisThe DAK-Health ("DAK-G") assumes that this procedure does not fall within the scope of antitrust law due to the lack of a selection decision and thus the non-discriminatory accessibility of all pharmaceutical companies Entry into force of the exclusive contract for glyceryl trinitrate, ATCC01DA02, as a result of a public procurement procedure in accordance with the regulations of Part 4 of the GWB with one or more contractual partners. In order to meet the diversity of potential contractors within the scope of the approval model, each pharmaceutical company will be able to conclude a framework contract at any time and under the same conditions during the contract period.The contract documents required for this purpose are available for download via the online portal www.dtvp.de/center under the link named under I.3).
  Requirements for the conclusion, or the later accession to the first time on 1.10.2019 in Compulsory contracts are the complete and timely transmission of the following evidence / explanations / attachments (available to the Download under the link under I.3) to the following contact person at the DAK-G:
  1) Letter of invitation;
  2) Current proof of entry in the trade or professional register (see III.1.1.);
  3) Self-declaration of the company (Annex A1), that none of the exclusion criteria according to -- 123, 124 GWB are present (see III.1.1.);
  4) Self-declaration that for those drugsfor which the interested party wishes to conclude a contract under this procedure, has a drug license and that the tenderer is entitled to sell at the inception of the contract (Appendix A2) (see III.1.1.);
  5) self-declaration by the company the legal requirements on the minimum wage and the tariff fidelity are observed and adhered to (Annex A3) (see III.1.1.);
  6)Recognition of the contractual stipulations of the DAK-G, in particular also the prescribed discounts by signing the contract stamped with a company stamp (twice in the original) by the interested party at the designated place;
  7) Appendices 1 and 2 to the contract (2 -fold in the original). The interested party has the medicines for the o. G. Enter drug, which contract subject
  8) Effective pre-qualification notification of DAK-G (see III.1.1 and III.1.2.)
  The documents must be submitted by post to:
  DAK-Health
  Henri Affinass (0032 50)
  Nagelsweg 27-31
  20097 Hamburg
  Furthermore, the attachment 2 as an Excel file at the same time to the mail address am_rabattvertraege@dak.de to send. Contracts under this model and to o. G. Active ingredient eFirst completed with effect from 1.10.2019 and ending on 30.9.2021. Interested parties who want to become contract partners for this date, have the o. G. Documents until the 5th of the previous month at o.g. Submit job. It depends on the timely access to the DAK-G. For the deadline is an electronic receipt of the complete documents to the above. E-mail address fromreaching. Later accessions are possible at any time. In order to be able to join during the term of the contract on the 1st or 15th of the following month, the o. G. Documents, regardless of the desired accession, the DAK-G are available until the 5th of the previous month. Example: The applicant`s wish to join should be 15.07.20xx (following month), the documents would have to be submitted until 05.06.20xx (Previous note). Note: The publication is done here using the Open Procedure form. As has already been made clear, this is not such a notice had to be used for technical reasons, as there is no form suitable for registration procedures.
  1) Current proof of registration in the professional or commercial register (nicht older than 6 months upon dispatch) in accordance with the legislation of the country in which the company is established, eg. Eg current commercial register extract; Copy is sufficient;
  2) Self-declaration by the company that none of the exclusion criteria according to -- 123, 124 GWB exists. Attachment A1 must be signed, stamped and submitted in original form;
  3)Self-declaration that for those medicines for which the interested party wishes to conclude a contract under this procedure, there is a drug license and that the tenderer is entitled to distribution at the beginning of the contract (Annex A2) (see III.1.1.);
  4 ) Self-declaration of the company that observes the legal requirements on the minimum wage and the tariff fidelityt and maintained (Annex A3). Attachment A3 should be signed, stamped with a company stamp and submitted in original form.
  DAK-Gesundheit has published a so-called pre-qualification procedure for pharmaceutical companies for the simplified participation in future drug rebate tenders via the European Notice Board (EU Notice 2015 / S 105-190319 of 3.6.2015). If the bidder has received an effective pre-qualification notification from DAK-Gesundheit in good time before submission of the documents, he needs the company-specific proof of suitability (proof of entry in the trade or professional register, self-declaration by the company that none of the exclusion criteria according to -- 123, 124 GWB is present, harmlesscertificate of legal health insurance, self-declaration minimum wage and tariff fidelity) with reference and enclosing the Praequalifikationsbescheides in copy no longer to be attached. Attachment A2 must always be attached. Accordingly, the DAK health pre-qualification notification also serves as proof of DAK health open-house procedures, regardless of the order valueNotice that, for those medicinal products for which the prospective buyer wishes to conclude the contract under this procedure, there is a marketing authorization and that the tenderer is entitled to sell at the beginning of the contract. Attachment A2 has to be signed, stamped and submitted in original. The DAK health has over the europaepublished a so-called pre-qualification procedure for pharmaceutical companies for simplified participation in future drug rebate tenders (EU Announcement 2015 / S 105-190319 of 3.6.2015). If the bidder has received an effective pre-qualification notification from DAK-Gesundheit in good time before submission of the documents, then this is requiredthe company-specific proof of suitability (proof of registration in the trade or professional register, self-declaration of the company that none of the exclusion criteria according to -- 123, 124 GWB is present, certificate of health insurance from the statutory health insurance, self-declaration minimum wage and tariff fidelity) under reference and enclosing the Praequalifikationsbescheides in Copy no longer beizufuegen. Attachment A2 must always be attached. The pre-qualification notification from DAK-Gesundheit also serves as proof in open-house procedures of DAK-Gesundheit.
  The tender documents can also be requested by e-mail from the contact point named under I.1) in the necessary individual case. The tender documents will then be sent by e-mail. Questions and hinte to the tender documents are to be sent by e-mail or in writing (by fax or letter) to the contact point named under I.1) by electronic means (via the tendering portal www.dtvp.de) or in necessary individual batches. They are to be formulated in German. Answers will be given to all entrepreneurs who submit the tender documents by means of a regihave made available in anonymised form. The answers are provided to the entrepreneurs by means of bidder communication via the allocation portal www.dtvp.de. Companies who have downloaded the tender documents without registration, have to follow the further communication on their own responsibility and if necessary to the o. G. KontThis publication does not constitute the award of a public service contract within the meaning of the 2014/24 / EU Procurement Coordination Directive of the European Parliament and of the Council or of the Public Procurement Law. In order to ensure the widest possible degree of transparency for the envisaged contracts, the publication is included in the Supplement zOfficial Journal of the European Union. In the absence of a corresponding publication form, the contract notice will be used. The resulting conceptual requirements, such as the process name "Open Procedure", are solely due to the use of this announcement form and the publication platform, another meaning, in particular a bottomProhibition under procurement regulations, unless they are legally binding, is not connected with this.
  Announcement ID: CXP4YM5DD4Q
  
  Internet address (URL): www.dak.de
• Documents:

 Tender Notice